Goldman Sachs
STRO icon

Goldman Sachs’s Sutro Biopharma STRO Stock Holding History

Goldman Sachs’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$677K Buy
27,187
+11,518
+74% +$208K ﹤0.01% 5379
2025
Q4 		$181K Buy
15,669
+6,858
+78% +$65.1K ﹤0.01% 6059
2025
Q3 		$76.5K Sell
8,811
-31,764
-78% -$270K ﹤0.01% 6120
2025
Q2 		$290K Sell
40,575
-130,637
-76% -$1.07M ﹤0.01% 5459
2025
Q1 		$1.11M Sell
171,212
-230
-0.1% -$3.62K ﹤0.01% 4600
2024
Q4 		$3.15M Sell
171,442
-3,185
-2% -$97.2K ﹤0.01% 3905
2024
Q3 		$6.04M Buy
174,627
+69,690
+66% +$2.73M ﹤0.01% 3176
2024
Q2 		$3.07M Buy
104,937
+24,663
+31% +$975K ﹤0.01% 3600
2024
Q1 		$4.54M Sell
80,274
-25,784
-24% -$1.14M ﹤0.01% 3179
2023
Q4 		$4.55M Sell
106,058
-3,081
-3% -$97.8K ﹤0.01% 3245
2023
Q3 		$3.79M Sell
109,139
-748
-0.7% -$32.6K ﹤0.01% 3232
2023
Q2 		$5.11M Sell
109,887
-40,174
-27% -$2M ﹤0.01% 3094
2023
Q1 		$6.93M Buy
150,061
+42,314
+39% +$2.69M ﹤0.01% 2752
2022
Q4 		$8.71M Buy
107,747
+13,690
+15% +$951K ﹤0.01% 2704
2022
Q3 		$5.22M Buy
94,057
+43,451
+86% +$2.57M ﹤0.01% 3090
2022
Q2 		$2.64M Buy
50,606
+10,368
+26% +$579K ﹤0.01% 3805
2022
Q1 		$3.31M Buy
40,238
+3,983
+11% +$379K ﹤0.01% 3754
2021
Q4 		$5.39M Buy
36,255
+3,639
+11% +$652K ﹤0.01% 3333
2021
Q3 		$6.16M Buy
32,616
+27,415
+527% +$5.21M ﹤0.01% 3178
2021
Q2 		$967K Sell
5,201
-2,138
-29% -$418K ﹤0.01% 4787
2021
Q1 		$1.67M Sell
7,339
-5,948
-45% -$1.41M ﹤0.01% 4156
2020
Q4 		$2.88M Buy
13,287
+11,473
+632% +$1.9M ﹤0.01% 3448
2020
Q3 		$182K Sell
1,814
-2,245
-55% -$212K ﹤0.01% 4948
2020
Q2 		$315K Buy
4,059
+2,666
+191% +$256K ﹤0.01% 4600
2020
Q1 		$142K Buy
1,393
+240
+21% +$25.2K ﹤0.01% 4841
2019
Q4 		$127K Buy
+1,153
New +$119K ﹤0.01% 5012
2018
Q4 		– Sell
-2,830
Closed -$425K – 5645
2018
Q3 		$425K Buy
+2,830
New +$427K ﹤0.01% 4502

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs's STRO Position: Q1 2026 in Review

Goldman Sachs increased its Sutro Biopharma (STRO) stake by 74% in Q1 2026, buying an estimated $208K and bringing the position to 27,187 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #5379.

Goldman Sachs first reported a position in STRO in Q3 2018 and has held it in 27 quarters since. The position peaked at $8.71M in Q4 2022. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Goldman Sachs held 27,187 shares of Sutro Biopharma worth $677K as of Q1 2026.
  • Goldman Sachs bought 11,518 Sutro Biopharma shares in Q1 2026, an estimated $208K.
  • Sutro Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5379 holding.
  • Goldman Sachs first reported a position in Sutro Biopharma in Q3 2018 and has held it in 27 quarters since.
  • Goldman Sachs's Sutro Biopharma position peaked at $8.71M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.